Table 2.
Baseline and demographic characteristics (intent-to-treat analysis set) for patients with evaluable cognitive scores.
| Total (N = 324) | |
|---|---|
| Agea (years), mean (SD) | 15.4 (1.54) |
| Age category, n (%) | |
| 12–14 years | 83 (25.6) |
| 15–17 years | 238 (73.5) |
| >17 years | 3 (0.9) |
| Sex, n (%) | |
| Boys | 203 (62.7) |
| Girls | 121 (37.3) |
| Race, n (%) | |
| White | 227 (70.1) |
| Black | 21 (6.5) |
| Asian | 75 (23.1) |
| Otherb | 1 (0.3) |
| Weight (kg), mean (SD) | 62.7 (15.03) |
| Baseline body weight category, n (%) | |
| <51 kg | 68 (21.0) |
| ≥51 kg | 256 (79.0) |
| Body mass index (kg/m2), mean (SD) | 22.2 (4.42) |
| Age at diagnosis of schizophrenia, mean (SD) (years) | 13.1 (2.41) |
| Schizophrenia type, n (%) | |
| Paranoid | 248 (76.5) |
| Disorganized | 24 (7.4) |
| Catatonic | 6 (1.9) |
| Undifferentiated | 42 (13.0) |
| Residual | 4 (1.2) |
| Baselinea PANSS total, mean (SD) | 83.2 (19.44) |
| PANSS Factor Scores, mean (SD) | |
| Positive symptoms | 22.9 (6.28) |
| Negative symptoms | 21.5 (6.07) |
| Disorganized thoughts | 19.6 (5.65) |
| Uncontrolled hostility/excitement | 9.8 (3.81) |
| Anxiety/depression | 9.4 (3.25) |
| Baselinea CGAS total, mean (SD) | 50.5 (13.85) |
Patients entered the open-label study with differing exposure to paliperidone ER, depending on whether they entered the open-label trial directly or from having participated in the previous double-blind trial.
a
Start of open-label study.
b
Includes one Hispanic patient and one patient classified as multi-racial (Black, Chinese, White, Indian). CGAS, Children Global Assessment Scale; PANSS, Positive and Negative Symptom Score.